

REFERENCES

1. Annex S. The World Health Report 2004. 2004 [updated 2004; cited 12 December 2009]; Available from: <http://www.who.int/whosis>.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer*. 2008; 127(12): 2893-917.
3. Attasara P, editor. *CANCER REGISTRY 2006*. Bangkok, Thailand: National Cancer Institute Department of Medical Services Ministry of Public Health Thailand; 2006.
4. John DM. Neoplasms of the lung, in *Harrison's Principles of Internal Medicine*. 16th ed. Dennis LK, et al., editor.; 2005.
5. Spiro SG. *Oxford Textbook Medicine*. 5th ed.: OUP Oxford; 2010.
6. Le Bras M, Delattre V, Bensaad K, Blandino G, Soussi T. Monoclonal antibodies raised against Xenopus p53 interact with human p73. *Oncogene*. 2002; 21(8): 1304-8.
7. p53 Protocols. Sumitra D, Swati PD, editors.: Springer; 2003.
8. Harlow E, Crawford LV, Pim DC, Williamson NM. Monoclonal antibodies specific for simian virus 40 tumor antigens. *J Virol*. 1981; 39(3): 861-9.
9. Lane DP, Stephen CW, Midgley CA, Sparks A, Hupp TR, Daniels DA, et al. Epitope analysis of the murine p53 tumour suppressor protein. *Oncogene*. 1996; 12(11): 2461-6.

10. Midgley CA, Owens B, Briscoe CV, Thomas DB, Lane DP, Hall PA. Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. *J Cell Sci.* 1995; 108 (Pt 5): 1843-8.
11. Moenner M, Pluquet O, Bouchecareilh M, Chevet E. Integrated endoplasmic reticulum stress responses in cancer. *Cancer Res.* 2007; 67(22): 10631-4.
12. Kumar V, et al. Robbins and Cotran pathologic basis of disease. 8th ed. Philadelphia: SAUNDERS ELSEVIER; 2009.
13. American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012.
14. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin.* 2005; 55(2): 74-108.
15. Lam WK. Lung cancer in Asian women-the environment and genes. *Respirology.* 2005; 10(4): 408-17.
16. World Health Organization Iafroc. IARC monographs on the evaluation of carcinogenic risks to humans. Tobacco smoke and involuntary smoking summary of data reported and evaluation. 2002; 83.
17. AIRNET epidemiologyworkgroup. Air pollution and the risks to human health. *epidemiology.* 2005.
18. Kress M, May E, Cassingena R, May P. Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum. *J Virol.* 1979; 31(2): 472-83.
19. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. *Nat Rev Cancer.* 2009; 9(10): 749-58.

20. Bensaad K, Rouillard D, Soussi T. Regulation of the cell cycle by p53 after DNA damage in an amphibian cell line. *Oncogene*. 2001; 20(29): 3766-75.
21. Bessard AC, Garay E, Lacronique V, Legros Y, Demarquay C, Houque A, et al. Regulation of the specific DNA binding activity of *Xenopus laevis* p53: evidence for conserved regulation through the carboxy-terminus of the protein. *Oncogene*. 1998; 16(7): 883-90.
22. Courtois S, Caron de Fromentel C, Hainaut P. p53 protein variants: structural and functional similarities with p63 and p73 isoforms. *Oncogene*. 2004; 23(3): 631-8.
23. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. *Nature*. 2009; 458(7242): 1127-30.
24. Tokino T, Nakamura Y. The role of p53-target genes in human cancer. *Crit Rev Oncol Hematol*. 2000; 33(1): 1-6.
25. Erhan Y, Korkut MA, Kara E, Aydede H, Sakarya A, Ilkgu O. Value of p53 protein expression and its relationship with short-term prognosis in colorectal cancer. *Ann Saudi Med*. 2002; 22(5-6): 377-80.
26. Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. *J Natl Cancer Inst*. 1996; 88(3-4): 173-82.
27. Rohan TE, Li SQ, Hartwick R, Kandel RA. p53 Alterations and protein accumulation in benign breast tissue and breast cancer risk: a cohort study. *Cancer Epidemiol Biomarkers Prev*. 2006; 15(7): 1316-23.
28. Smith DR, Ji CY, Goh HS. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. *Br J Cancer*. 1996; 74(2): 216-23.

29. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. *Clin Cancer Res.* 2006; 12(4): 1157-67.
30. Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. *Br J Cancer.* 1999; 80(12): 1968-73.
31. Caron FC, May LF, Mouriesse H, Lemerle J, Chandrasekaran K, May P. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. *Int J Cancer.* 1987; 39: 185-9.
32. Lane DP. Cancer. p53, guardian of the genome. *Nature.* 1992; 358(6381): 15-6.
33. Blattner C. Regulation of p53: the next generation. *Cell Cycle.* 2008; 7(20): 3149-53.
34. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. *Cell.* 1994; 78(4): 703-11.
35. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. *Cancer Res.* 1991; 51(23 Pt 1): 6304-11.
36. Harvey M, McArthur MJ, Montgomery CA, Jr., Butel JS, Bradley A, Donehower LA. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. *Nat Genet.* 1993; 5(3): 225-9.
37. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Jr., Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. *Nature.* 1992; 356(6366): 215-21.

38. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. *Cell Mol Life Sci.* 1999; 55(1): 96-107.
39. Thut CJ, Chen JL, Klemm R, Tjian R. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. *Science.* 1995; 267(5194): 100-4.
40. Thut CJ, Goodrich JA, Tjian R. Repression of p53-mediated transcription by MDM2: a dual mechanism. *Genes Dev.* 1997; 11(15): 1974-86.
41. Lev Bar-Or R, Maya R, Segel LA, Alon U, Levine AJ, Oren M. Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. *Proc Natl Acad Sci U S A.* 2000; 97(21): 11250-5.
42. Chene P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. *Nat Rev Cancer.* 2003; 3(2): 102-9.
43. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. *Nature.* 2000; 408(6810): 307-10.
44. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. *Science.* 1991; 253(5015): 49-53.
45. Qu L, Koromilas AE. Control of tumor suppressor p53 function by endoplasmic reticulum stress. *Cell Cycle.* 2004; 3(5): 567-70.
46. Kaufman RJ. Orchestrating the unfolded protein response in health and disease. *J Clin Invest.* 2002; 110(10): 1389-98.
47. Sitia R, Braakman I. Quality control in the endoplasmic reticulum protein factory. *Nature.* 2003; 426(6968): 891-4.

48. Qu L, Huang S, Baltzis D, Rivas-Estilla AM, Pluquet O, Hatzoglou M, et al. Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3beta. *Genes Dev.* 2004; 18(3): 261-77.
49. Mogaki M, Hirota M, Chaney WG, Pour PM. Comparison of p53 protein expression and cellular localization in human and hamster pancreatic cancer cell lines. *Carcinogenesis.* 1993; 14(12): 2589-94.
50. Lain S, Xirodimas D, Lane DP. Accumulating active p53 in the nucleus by inhibition of nuclear export: a novel strategy to promote the p53 tumor suppressor function. *Exp Cell Res.* 1999; 253(2): 315-24.
51. Stiewe T. The p53 family in differentiation and tumorigenesis. *Nat Rev Cancer.* 2007; 7(3): 165-8.
52. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. *Mol Cell.* 1998; 2(3): 305-16.
53. Trink B, Okami K, Wu L, Sriuranpong V, Jen J, Sidransky D. A new human p53 homologue. *Nat Med.* 1998; 4(7): 747-8.
54. Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, Smits AP, et al. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. *Cell.* 1999; 99(2): 143-53.
55. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. *Nature.* 1999; 398(6729): 714-8.

56. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. *Nature*. 2000; 404(6773): 99-103.
57. Finlan LE, Hupp TR. p63: the phantom of the tumor suppressor. *Cell Cycle*. 2007; 6(9): 1062-71.
58. Rosenbluth JM, Pietenpol JA. The jury is in: p73 is a tumor suppressor after all. *Genes Dev*. 2008; 22(19): 2591-5.
59. Kaelin WG, Jr. The p53 gene family. *Oncogene*. 1999; 18(53): 7701-5.
60. Bourdon JC. p53 Family isoforms. *Curr Pharm Biotechnol*. 2007; 8(6): 332-6.
61. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Nozoe T, et al. Expression of the p53 family in lung cancer. *Anticancer Res*. 2006; 26(3A): 1785-90.
62. Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. *EMBO J*. 1990; 9(5): 1595-602.
63. Bensaad K, Le Bras M, Unsal K, Strano S, Blandino G, Tominaga O, et al. Change of conformation of the DNA-binding domain of p53 is the only key element for binding of and interference with p73. *J Biol Chem*. 2003; 278(12): 10546-55.
64. คณัฏ ระวังสุข. Polyclonal Antibody ที่ถูกกระตุ้นการสร้างโดย p53 ของหนูทำ

ปฏิกิริยาได้กับโปรตีนขนาด 83 kDa ของคน ซึ่งมีการแสดงออกที่สูงขึ้นในเนื้อเยื่อมะเร็งแต่ไม่ใช่


ในเนื้อเยื่อปกติของผู้ป่วยมะเร็งปอด [ภาคนิพนธ์วิทยาสตรบัณฑิตเทคนิคการแพทย์].

เชียงใหม่: มหาวิทยาลัยเชียงใหม่; 2551.

65. Mitprasat M, Roytrakul S, Jiemsup S, Boonseng O, Yokthongwattana K. Leaf proteomic analysis in cassava (*Manihot esculenta*, Crantz) during plant development, from planting of stem cutting to storage root formation. *Planta*. 2011; 233(6): 1209-21.
66. Chan SW, Egan PA. Hepatitis C virus envelope proteins regulate CHOP via induction of the unfolded protein response. *FASEB J*. 2005; 19(11): 1510-2.
67. Ruddock LW, Molinari M. N-glycan processing in ER quality control. *J Cell Sci*. 2006; 119(Pt 21): 4373-80.
68. Ellgaard L, Molinari M, Helenius A. Setting the standards: quality control in the secretory pathway. *Science*. 1999; 286(5446): 1882-8.
69. Wang N, Daniels R, Hebert DN. The cotranslational maturation of the type I membrane glycoprotein tyrosinase: the heat shock protein 70 system hands off to the lectin-based chaperone system. *Mol Biol Cell*. 2005; 16(8): 3740-52.
70. Lee AS, Hendershot LM. ER stress and cancer. *Cancer Biol Ther*. 2006; 5(7): 721-2.
71. Magyar JE, Gamberucci A, Konta L, Margittai E, Mandl J, Banhegyi G, et al. Endoplasmic reticulum stress underlying the pro-apoptotic effect of epigallocatechin gallate in mouse hepatoma cells. *Int J Biochem Cell Biol*. 2009; 41(3): 694-700.
72. Gamberucci A, Konta L, Colucci A, Giunti R, Magyar JE, Mandl J, et al. Green tea flavonols inhibit glucosidase II. *Biochem Pharmacol*. 2006; 72(5): 640-6.
73. Ranganathan AC, Adam AP, Zhang L, Aguirre-Ghiso JA. Tumor cell dormancy induced by p38SAPK and ER-stress signaling: an adaptive advantage for metastatic cells? *Cancer Biol Ther*. 2006; 5(7): 729-35.

74. Cho HY, Thomas S, Golden EB, Gaffney KJ, Hofman FM, Chen TC, et al. Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress. *Cancer Lett.* 2009; 282(1): 87-97.
75. Jakobsen CH, Storvold GL, Bremseth H, Follestad T, Sand K, Mack M, et al. DHA induces ER stress and growth arrest in human colon cancer cells: associations with cholesterol and calcium homeostasis. *J Lipid Res.* 2008; 49(10): 2089-100.
76. Zhang LJ, Chen S, Wu P, Hu CS, Thorne RF, Luo CM, et al. Inhibition of MEK blocks GRP78 up-regulation and enhances apoptosis induced by ER stress in gastric cancer cells. *Cancer Lett.* 2009; 274(1): 40-6.
77. Elbein AD. Glycosidase inhibitors as antiviral and/or antitumor agents. *Semin Cell Biol.* 1991; 2(5): 309-17.
78. Elbein AD. Glycosidase inhibitors: inhibitors of N-linked oligosaccharide processing. *FASEB J.* 1991; 5(15): 3055-63.
79. Horn HF, Vousden KH. Coping with stress: multiple ways to activate p53. *Oncogene.* 2007; 26(9): 1306-16.
80. Colman MS, Afshari CA, Barrett JC. Regulation of p53 stability and activity in response to genotoxic stress. *Mutat Res.* 2000; 462(2-3): 179-88.
81. Amundson SA, Myers TG, Fornace AJ, Jr. Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. *Oncogene.* 1998; 17(25): 3287-99.
82. Pluquet O, Qu LK, Baltzis D, Koromilas AE. Endoplasmic reticulum stress accelerates p53 degradation by the cooperative actions of Hdm2 and glycogen synthase kinase 3beta. *Mol Cell Biol.* 2005; 25(21): 9392-405.

83. Stavridi ES, Halazonetis TD. p53 and stress in the ER. *Genes Dev.* 2004; 18(3): 241-4.



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่

Copyright© by Chiang Mai University
All rights reserved